Although the cause of RV dysfunction and the feasibility of therapeutically targeting the RVH are uncertain, RV dilatation was observed in WT mice but not in HEX-Tg mice under chronic hypoxia (Fig. 6C), suggesting that therapies that target RVH by HEXIM1 might be beneficial in PAH. This evidence concerns the gene HEXIM1 and pulmonary arterial hypertension.